Rapid Readout: ARASENS: Darolutamide Versus Placebo in Combination With ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Selected Ongoing Trials With Darolutamide In Prostate Cancer | Download Scientific Diagram
Interpreting Data From the ARASENS Trial in Metastatic HSPC
mHSPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC
Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Hormonal Therapy for mCSPC: With So Many Options, How Does One Choose?
ASCO 2020: Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to Androgen Deprivation Therapy for Non-metastatic Castration-Resistant Prostate Cancer
Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data - Bayer News
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer
Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New Standard of Care for mHSPC
Darolutamide For Castration-Resistant Prostate Cancer. - Abstract - Europe PMC
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting | SpringerLink
ASCO GU 2022: Discussion on the ARASENS and PRESIDE Trials
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
ASCO GU 2022: Overall Survival With Darolutamide Versus Placebo in Combination With Docetaxel and Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in the Phase 3 ARASENS Trial
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer | NEJM
Recent Advances in the Management of Metastatic Prostate Cancer | JCO Oncology Practice
Nubeqa (darolutamide) increases overall survival in men with mCSPC/HSPC when added to androgen-deprivation treatment (ADT) with docetaxel: ARASENS phase III study - DelveInsight Business Research
